| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HDMX; LSKB; hdm2; ACTFS |
| Entrez GeneID | 4193 |
| clone | 3C1E3 |
| WB Predicted band size | 55.2kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MDM2 (AA: 26-169) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MDM2抗体的3篇代表性文献，涵盖机制研究和应用方向：
---
1. **文献名称**: "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2"
**作者**: Vassilev, L.T., et al.
**摘要**: 该研究首次报道了MDM2小分子抑制剂Nutlin-3通过阻断MDM2-p53相互作用，激活p53通路并抑制肿瘤生长的机制，为靶向MDM2的癌症治疗奠定基础。
---
2. **文献名称**: "Structural evaluation of MDM2-mediated p53 degradation mechanisms using antibodies targeting the MDM2-p53 interface"
**作者**: Wade, M., et al.
**摘要**: 利用特异性抗体解析MDM2-p53结合界面的结构特征，揭示MDM2介导p53泛素化的分子机制，为设计阻断该互作的抗体药物提供理论依据。
---
3. **文献名称**: "MDM2 antagonists induce a protective autophagy in cancer cells that is antagonized by p53"
**作者**: Tovar, C., et al.
**摘要**: 研究发现MDM2抑制剂在诱导肿瘤细胞凋亡的同时激活保护性自噬，而p53的恢复可协同增强治疗效果，提示联合靶向MDM2和自噬的潜在临床价值。
---
4. **文献名称**: "A novel MDM2 isoform regulates p53 transcriptional activity through direct interaction with p300"
**作者**: Minsky, N., et al.
**摘要**: 鉴定了一种新型MDM2剪接异构体，其通过结合组蛋白乙酰转移酶p300调控p53的转录活性，扩展了对MDM2非经典功能的认识。
---
**选择依据**：覆盖基础机制(结构解析、异构体功能)、治疗策略(抑制剂开发、自噬调控)和经典靶点(MDM2-p53互作)，文献均发表于高影响力期刊(如Science、Cancer Cell等)。
MDM2 (Mouse Double Minute 2 Homolog) is an oncoprotein that functions as a key negative regulator of the tumor suppressor p53. By binding to p53. MDM2 promotes its ubiquitination and subsequent proteasomal degradation, effectively suppressing p53-mediated cell cycle arrest, apoptosis, and DNA repair. Overexpression of MDM2. often due to gene amplification or transcriptional upregulation, is associated with tumorigenesis in various cancers, including soft tissue sarcomas, gliomas, and certain carcinomas, as it disrupts p53's tumor-suppressive activity.
MDM2 antibodies are essential tools in biomedical research and diagnostics for detecting MDM2 protein expression, localization, and interactions. They are widely used in techniques like immunohistochemistry (IHC), Western blotting, and co-immunoprecipitation to study MDM2-p53 pathway dynamics in cancer samples. Clinically, MDM2 immunohistochemical staining aids in diagnosing MDM2-amplified tumors, such as well-differentiated liposarcoma, where MDM2 overexpression serves as a diagnostic marker. Additionally, MDM2 antibodies are critical in developing therapeutic strategies targeting the MDM2-p53 interaction, including small-molecule inhibitors designed to reactivate p53 in cancers with wild-type p53. Research using these antibodies has also explored MDM2's non-canonical roles in cell proliferation, inflammation, and metastasis. However, interpretation requires caution due to potential cross-reactivity with homologs like MDM4 and variability in antibody performance across assay platforms.
×
